Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Secoisolariciresinol-diglucoside has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
The gut microbiota performs the deglycosylation, demethylation and dehydroxylation steps that turn the plant lignan into the mammalian lignans. People differ several-fold in how much enterolactone they produce from the same intake, and that difference tracks with microbial composition. A probiotic does not guarantee higher conversion, because the specific taxa involved are not fully mapped. What is settled is that conversion is bacterial, so anything that flattens the microbiota lowers output.
Enterolignan production happens in the colon, where fermentable substrate drives bacterial density and activity. Inulin-type fructans are established substrate for that community. The link from more substrate to more enterolactone is inferred rather than directly demonstrated for this pairing. It is a reasonable formulation choice, not a measured effect.
Cold pressing sends the alpha-linolenic acid into the oil and leaves the water-soluble SDG in the meal. Straight flaxseed oil therefore carries almost no lignan unless the maker adds a lignan-rich fraction back in. That is why some products are labelled high-lignan flax oil. It is a formulation fact worth knowing when reading a label.
Deglycosylation is the entry step and it requires bacterial beta-glucosidase, an activity well described in Lactobacillus species. The later demethylation and dehydroxylation steps involve other taxa, so no single strain completes the pathway. Adding one strain does not reliably raise enterolactone in people. Read this as one step in a chain rather than a solution to low conversion.
Enterolactone formation requires several sequential bacterial reactions in the colon. Anything that shortens transit reduces the window for those reactions. Psyllium is mostly a gelling rather than a rapidly fermented fibre, so the size of any effect is unclear and has not been measured for this pair. It is worth flagging rather than acting on.
Enterolactone is a weak phytoestrogen and interest in lignans for bone density rests on that receptor interaction. Calcium supplies the mineral substrate itself. These are unrelated mechanisms that happen to share an endpoint of interest. Human evidence that lignan intake changes bone density measures is not established.
Nothing specific on file for Secoisolariciresinol-diglucoside. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 4 we read for Secoisolariciresinol-diglucoside. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.